Notably, the combination of BMS-986016 and nivolumab (anti-PD-1) exhibited exciting preliminary efficacy in melanoma patients who were refractory to the previous anti–PD-1/PD-L1 therapy (NCT01968109). Here, PDCD1 is linked to melanoma.